Delta9-Tetrahydrocannabinol
Complex Regional Pain Syndromes
Ludwig-Maximilians - University of MunichPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Complex Regional Pain Syndromes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE Endo USA Inc., a Keenova Therapeutics Company | Phase 4 | BB |
IBUPROFEN Amgen | Phase 3 | BB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Endo USA Inc., a Keenova Therapeutics Company | Phase 4 | BB |
Naltrexone Hospital for Special Surgery, New York | Phase 4 | BB |
FENTANYL Janssen Pharmaceutical K.K. | Phase 3 | BB |
View all 19 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →